CompletedPHASE1, PHASE2NCT02921061

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Studying Mixed phenotype acute leukemia

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Fred Hutchinson Cancer Center
Principal Investigator: Roland Walter, MD PhD
Fred Hutch/University of Washington Cancer Consortium
Intervention: Cladribine(drug)
Enrollment: 28 enrolled
Eligibility: 18 years · All sexes
Timeline: 2016 – 2018

Study locations (1)

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02921061 on ClinicalTrials.gov

Other trials for Mixed phenotype acute leukemia

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT07222579
Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
West Virginia University

See all trials for Mixed phenotype acute leukemia →

← Back to all trials